Google
TARA — PROTARA THERAPEUTICS INC (Healthcare >> Biotechnology)
TARA FAQ
What is TARA's ROE?
PROTARA THERAPEUTICS INC reports a Return on Equity (ROE) of -34.94%.
What is TARA's dividend yield?
PROTARA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is TARA's Deepscope Quality Score?
Deepscope rates TARA's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TARA?
Deepscope's AI Timing Score for TARA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TARA belong to?
PROTARA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.16
Price
-0.25
(-5.67%)
Day Change
|
|
|---|
TARA, the overall quality is not good ( Quality = 8) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 49 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.16 |
| PBV / Sector |
1.37 / 4.63
GOOD
|
| Earning Per Share | -1.06 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.61 M
GREAT
|
| Average 1W Daily Value |
2.24 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:43 |
| Symbol | TARA |
| Name | PROTARA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 56.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 247.86 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 345 Park Avenue South, New York, NY, United States, 10010
Phone: 646 844 0337
Website: https://www.protaratx.com
Sector: Healthcare >> Biotechnology
Description: Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
